➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Express Scripts
McKinsey
Harvard Business School
Moodys

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TECOVIRIMAT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for tecovirimat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00431951 Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2007-02-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00431951 Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers Completed SIGA Technologies Phase 1 2007-02-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00728689 Phase I Trial of an Investigational Small Pox Medication Completed National Institutes of Health (NIH) Phase 1 2008-08-01 The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00728689 Phase I Trial of an Investigational Small Pox Medication Completed SIGA Technologies Phase 1 2008-08-01 The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00907803 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed National Institutes of Health (NIH) Phase 2 2009-06-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
NCT00907803 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed SIGA Technologies Phase 2 2009-06-01 The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tecovirimat

Condition Name

Condition Name for tecovirimat
Intervention Trials
Smallpox 3
Orthopoxviral Disease 2
Monkeypox 1
Monkey Pox 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for tecovirimat
Intervention Trials
Smallpox 3
Monkeypox 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for tecovirimat

Trials by Country

Trials by Country for tecovirimat
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for tecovirimat
Location Trials
Florida 3
California 2
Texas 1
South Carolina 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for tecovirimat

Clinical Trial Phase

Clinical Trial Phase for tecovirimat
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for tecovirimat
Clinical Trial Phase Trials
Completed 3
Active, not recruiting 1
Available 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for tecovirimat

Sponsor Name

Sponsor Name for tecovirimat
Sponsor Trials
SIGA Technologies 4
National Institutes of Health (NIH) 2
Biomedical Advanced Research and Development Authority 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for tecovirimat
Sponsor Trials
Industry 4
NIH 3
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Mallinckrodt
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.